Distribution Agreement Will Streamline Methotrexate Determinations
|
By LabMedica International staff writers Posted on 16 Nov 2014 |
|
Measurement of levels of the anticancer and anti-autoimmune disease drug methotrexate in human serum or plasma will be streamlined by the integration of a quantitative methotrexate assay into the menu of a popular line of clinical chemistry autoanalyzers.
Methotrexate, which acts by inhibiting the metabolism of folic acid, was originally designed as a chemotherapeutic drug (using high doses). In low doses methotrexate is a generally safe and well tolerated drug for the treatment of certain autoimmune diseases. Because of its effectiveness, low-dose methotrexate is now first-line therapy for the treatment of rheumatoid arthritis.
The ARK Methotrexate Assay produced by ARK Diagnostics (Fremont, CA, USA) is intended for the quantitative determination of methotrexate in human serum or plasma on automated clinical chemistry analyzers. The measurements obtained are used in monitoring levels of methotrexate to help ensure appropriate therapy.
ARK Diagnostics has signed a distribution agreement that will enable laboratories to integrate its methotrexate test into the Roche (Basel, Switzerland) therapeutic drug monitoring (TDM) menu for its cobas c 501 and cobas c 502 clinical chemistry analyzers.
"Using the ‘partner channel’ approach to integrate our Methotrexate test into the menu on Roche analyzers will enable many more clinical laboratories to expand the testing services they can offer to physicians for therapeutic drug monitoring," said Robert O’Malley, vice president of marketing, sales, and service at ARK Diagnostics. "We look forward to further collaboration with Roche in the field of drug monitoring tests."
"Roche is committed to providing a comprehensive menu of assays to support the varying needs of our customers. The addition of ARK’s Methotrexate test to the Roche test menu will provide access for our customers to a specialized test for cancer drug monitoring with proven quality and performance," said Randy Pritchard, senior vice president of Roche Professional Diagnostics. "This partnership demonstrates our commitment to finding innovative ways to offer a more comprehensive TDM portfolio."
Related Links:
ARK Diagnostics
Roche
Methotrexate, which acts by inhibiting the metabolism of folic acid, was originally designed as a chemotherapeutic drug (using high doses). In low doses methotrexate is a generally safe and well tolerated drug for the treatment of certain autoimmune diseases. Because of its effectiveness, low-dose methotrexate is now first-line therapy for the treatment of rheumatoid arthritis.
The ARK Methotrexate Assay produced by ARK Diagnostics (Fremont, CA, USA) is intended for the quantitative determination of methotrexate in human serum or plasma on automated clinical chemistry analyzers. The measurements obtained are used in monitoring levels of methotrexate to help ensure appropriate therapy.
ARK Diagnostics has signed a distribution agreement that will enable laboratories to integrate its methotrexate test into the Roche (Basel, Switzerland) therapeutic drug monitoring (TDM) menu for its cobas c 501 and cobas c 502 clinical chemistry analyzers.
"Using the ‘partner channel’ approach to integrate our Methotrexate test into the menu on Roche analyzers will enable many more clinical laboratories to expand the testing services they can offer to physicians for therapeutic drug monitoring," said Robert O’Malley, vice president of marketing, sales, and service at ARK Diagnostics. "We look forward to further collaboration with Roche in the field of drug monitoring tests."
"Roche is committed to providing a comprehensive menu of assays to support the varying needs of our customers. The addition of ARK’s Methotrexate test to the Roche test menu will provide access for our customers to a specialized test for cancer drug monitoring with proven quality and performance," said Randy Pritchard, senior vice president of Roche Professional Diagnostics. "This partnership demonstrates our commitment to finding innovative ways to offer a more comprehensive TDM portfolio."
Related Links:
ARK Diagnostics
Roche
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Automated MALDI-TOF MS System
EXS 3000
Latest Industry News
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read more
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Technology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read more
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more